ISTH guidelines for antithrombotic treatment in COVID-19

Autor: Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, Ryan Zarychanski, Helaine E. Resnick, Charlotte A. Bradbury, Jean Marie Connors, Anna Falanga, Toshiaki Iba, Scott Kaatz, Jerrold H. Levy, Saskia Middeldorp, Tracy Minichiello, Eduardo Ramacciotti, Charles Marc Samama, Jecko Thachil, Lisa Broxmeyer, null International Society on Thrombosis and Haemostasis

Publikováno v: Journal of thrombosis and haemostasis, 20(10), 2214-2225. Wiley-Blackwell
2022, ' ISTH guidelines for antithrombotic treatment in COVID-19 ', Journal of Thrombosis and Haemostasis, vol. 20, no. 10, pp. 2214-2225 . https://doi.org/10.1111/jth.15808
Journal of Thrombosis and Haemostasis, 20, 2214-2225
Journal of Thrombosis and Haemostasis, 20, 10, pp. 2214-2225

Contains fulltext : 282327.pdf (Publisher’s version ) (Closed access) Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Op

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c98fdd43645a7a7eae119a5ed1a26d
https://pure.amc.nl/en/publications/isth-guidelines-for-antithrombotic-treatment-in-covid19(83f1bdb5-2c91-4f60-b3cf-32d76d492231).html